This study will be conducted in parallel with an ongoing Phase 2b study (QRK202) in diabetic macular edema (DME). The OAG study will evaluate the potential of PF-655 to enhance visual function in glaucoma. Under the amended agreement, should Pfizer assume development and potential commercialization of PF-655 in either or both indications following review of the Phase 2a PF-655 data, Quark will receive option exercise payments and be will eligible to receive development and regulatory milestones specific to each indication, as well as sales milestones and royalties. Quark may be eligible to receive additional total payments of up to approximately $165 million associated with development and approval of PF-655 for OAG. (Source: Medical News (via PRIMEZONE)) read more..
Wednesday, 2 May 2012
Diabetic Macular Edema-Quark Pharmaceuticals-Glaucoma-Oag
Friday, 27 April 2012
Watson Pharmaceuticals-Diabetic Macular Edema-Ampio Pharmaceuticals-Iridex Corporation
MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse™ technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called... read more..
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing... read more..
Equinix, Watson Pharmaceuticals Among Stocks Hitting 52-Week Highs Thursday
Equinix, Watson Pharmaceuticals Among Stocks Hitting 52-Week Highs Thursday
Fox Business - 18 hours ago
While trading on above-average volume, Equinix (EQIX) climbed today, reaching and then surpassing its previous 52-week high of $161.56. read more..